RE:RE:NewA 40% drop today wasn't justified in my opinion. The valuation is ridiculous - even if they only do $6 EPS for 2016, that gives it a current P/E multiple of 1.67... Find me a another company so undervalued, nothing even comes close. Nothing really indicates they are going out of business and CXR could be bought by a larger pharma company to a much larger premium to this share price.
$13 s/p just way too oversold and undervalued, the earnings/news wasn't bad enough to justify dropping it to these levels I would say... This company is still generating great cash flow, managing its debt well, and will eventually find a more fair valuation once the fear subsides.